Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Neurocrine Biosciences After Earnings Report

Share:
Related NBIX
Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health
What Should Biotech Investors Do Now?

In a report published Monday, Jefferies reiterated its Buy rating on Neurocrine Biosciences (NASDAQ: NBIX), and slightly raised its price target from $13.00 to $14.00.

Jefferies noted, “NBIX reported 4Q12 earnings per share and announced 2013 guidance. The next major catalyst for shares will be the data for ‘854 in movement disorders in May. We would be buyers ahead of these data and see significant upside potential as we can justify the entire valuation of NBIX on sales of elagolix for endometriosis.”

Neurocrine Biosciences closed on Friday at $10.84.

Latest Ratings for NBIX

DateFirmActionFromTo
Jul 2015Leerink SwannAssumesOutperform
Jun 2015Piper JaffrayMaintainsOverweight
Mar 2015JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (NBIX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters